FDA Inspection 1218002 — BioGenetics Corporation
The FDA completed an inspection of BioGenetics Corporation on September 5, 2023 in Mountainside, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 5, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Mountainside, NJ (United States)